150 related articles for article (PubMed ID: 2471025)
1. Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.
De Simone C; Albertini F; Almaviva M; Angarano G; Chiodo F; Costigliola P; Delia S; Ferlini A; Gritti F; Mazzarello G
Med Oncol Tumor Pharmacother; 1989; 6(1):63-7. PubMed ID: 2471025
[TBL] [Abstract][Full Text] [Related]
2. Isoprinosine (inosine pranobex BAN, INPX) in the treatment of AIDS and other acquired immunodeficiencies of clinical importance.
Glasky AJ; Gordon JF
Cancer Detect Prev Suppl; 1987; 1():597-609. PubMed ID: 2446760
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients.
De Simone C; Ferrazzi M; Bitonti F; Falciano M; Tzantzoglou S; Delia S; Sorice F
Immunopharmacol Immunotoxicol; 1988; 10(4):437-41. PubMed ID: 2469710
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of inosine pranobex and acyclovir.
Mindel A
Am J Med; 1988 Aug; 85(2A):7-9. PubMed ID: 2457315
[TBL] [Abstract][Full Text] [Related]
5. Inosine pranobex in the treatment of HIV infection: a review.
De Simone C; Famularo G; Tzantzoglou S; Moretti S; Jirillo E
Int J Immunopharmacol; 1991; 13 Suppl 1():19-27. PubMed ID: 1726683
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.
Pedersen C; Sandström E; Petersen CS; Norkrans G; Gerstoft J; Karlsson A; Christensen KC; Håkansson C; Pehrson PO; Nielsen JO
N Engl J Med; 1990 Jun; 322(25):1757-63. PubMed ID: 1693173
[TBL] [Abstract][Full Text] [Related]
7. Influence of methisoprinol (isoprinosine) on HIV-infected human lymphocytes: in vitro immunological, virological, and ultrastructural studies.
De Simone C; De Marco F; Arancia G; Tzantzoglou S; Paradisi S; Sorice F
J Clin Lab Anal; 1989; 3(1):26-33. PubMed ID: 2469781
[TBL] [Abstract][Full Text] [Related]
8. Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS.
Bekesi JG; Tsang PH; Wallace JI; Roboz JP
J Clin Lab Immunol; 1987 Dec; 24(4):155-61. PubMed ID: 2452254
[TBL] [Abstract][Full Text] [Related]
9. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Campoli-Richards DM; Sorkin EM; Heel RC
Drugs; 1986 Nov; 32(5):383-424. PubMed ID: 2431857
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study.
Mohanty KC; Scott CS
Genitourin Med; 1986 Oct; 62(5):352-5. PubMed ID: 2429908
[TBL] [Abstract][Full Text] [Related]
11. Study of the antiallergic component of inosine pranobex (Inosiplex, Isoprinosine).
Schmutzler W; Neukirch B; Ziesche R
Int Arch Allergy Appl Immunol; 1989; 88(1-2):244-6. PubMed ID: 2468618
[TBL] [Abstract][Full Text] [Related]
12. Inosiplex treatment of acquired immunodeficiencies: a clinical model for effective immunomodulation.
Glasky AJ; Gordon J
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):35-40. PubMed ID: 2422507
[TBL] [Abstract][Full Text] [Related]
13. A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy.
Wallace JI; Bekesi JG
Clin Immunol Immunopathol; 1986 Apr; 39(1):179-86. PubMed ID: 2419019
[TBL] [Abstract][Full Text] [Related]
14. Clinical. A new approach to combat viruses.
Hopkins S
Nurs Mirror; 1985 May; 160(18):28-9. PubMed ID: 2581230
[No Abstract] [Full Text] [Related]
15. [Immunological and clinical study on therapeutic efficacy of inosine pranobex].
Gołebiowska-Wawrzyniak M; Markiewicz K; Kozar A; Derentowicz P; Czerwińska-Kartowicz I; Jastrzebska-Janas K; Wacławek J; Wawrzyniak ZM; Siwińska-Gołebiowska H
Pol Merkur Lekarski; 2005 Sep; 19(111):379-82. PubMed ID: 16358878
[TBL] [Abstract][Full Text] [Related]
16. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.
Sliva J; Pantzartzi CN; Votava M
Adv Ther; 2019 Aug; 36(8):1878-1905. PubMed ID: 31168764
[TBL] [Abstract][Full Text] [Related]
17. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.
Beran J; Šalapová E; Špajdel M;
BMC Infect Dis; 2016 Nov; 16(1):648. PubMed ID: 27821093
[TBL] [Abstract][Full Text] [Related]
18. Inosine pranobex--only for use in controlled trials.
Drug Ther Bull; 1986 Dec; 24(24):95-6. PubMed ID: 2433117
[No Abstract] [Full Text] [Related]
19. [Immunomodulating treatment of patients with HIV infection].
Skotnicki AB; Kornaszewski W
Przegl Dermatol; 1989; 76(4):285-91. PubMed ID: 2483589
[No Abstract] [Full Text] [Related]
20. ACTH--inosine pranobex in the treatment of AIDS. Encouraging results.
Addo E; McFarlane H; Parsad K
West Indian Med J; 1989 Sep; 38(3):142-7. PubMed ID: 2482585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
